A Single Arm Phase 2 Study to Evaluate the Safety and Efficacy of Nab-Paclitaxel in Subjects With Previously Treated Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2017
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 09 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Dec 2014 Planned End Date changed from 1 Feb 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov.